Matches in SemOpenAlex for { <https://semopenalex.org/work/W2357863562> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2357863562 abstract "Purpose: To study the short-term efficacy and toxicity of the neoajuvant chemotherapy with epirubicin (EPI) plus paclitaxel( TAX) in treatment of patients with breast cancer. Methods: 20 patients with stage Ⅱ,Ⅲ breast cancer were treated with paclitaxel plus epirubicin (TE) for 2 - 4 cycles every 3 weeks, their clinical response and the toxicity were assessed after 2-4 cycles of neoajuvant chemotherapy, and they are compared with those of the patients treated with vinorelbine plus epirubicin( VE) as neoadjuvant chemotherapy. Patients in TE arm received epirubicin 60 mg/m2 by intravenous injection on d 1, paclitaxel 150 mg/m2 by 3-hour continuous infusion on d 2, 3 weeks was 1 cycle. Patients assigned to the VE arm received epirubicin 60 mg/m2 by intravenous injection on d 1, vinorelbine 30 mg/m by intravenous injection on d 1 and d 8, 4 weeks was 1 cycle. All patients were treated by modified radical operation after neoajuvant chemotherapy. Results: The overall response rate( RR) was 80% (16/20) both in TE arm and VE arm. There were 3(15%) clinical complete response( cCR) and 2(10%) pathologic complete response ( pCR) in every arm. No patient showed progressive disease. A higher proportion of RR and pCR was observed in patients with 4 cycles of neoajuvant chemotherapy than those with 2 cycles in the two groups. The major toxicity, including leukopenia, gastroenteric reaction, flushing of face and phlebitis, were similar in both groups, but fatigue, alopecia and neurotoxicity were more severe in VE arm than in TE arm(P0.05), myalgia and cephalalgia were more severe in the TE arm than in VE arm(P 0. 05). Conclusions: The two different regimens used as neoajuvant chemotherapy for breast cancer were both effective and their results were similar. The side effects in VE was higher than that in TE, but were all tolerable." @default.
- W2357863562 created "2016-06-24" @default.
- W2357863562 creator A5065869973 @default.
- W2357863562 date "2004-01-01" @default.
- W2357863562 modified "2023-09-25" @default.
- W2357863562 title "Neoadjuvant chemotherapy with epirubicin plus paclitaxel in treatment of patients with breast cancer" @default.
- W2357863562 hasPublicationYear "2004" @default.
- W2357863562 type Work @default.
- W2357863562 sameAs 2357863562 @default.
- W2357863562 citedByCount "0" @default.
- W2357863562 crossrefType "journal-article" @default.
- W2357863562 hasAuthorship W2357863562A5065869973 @default.
- W2357863562 hasConcept C121608353 @default.
- W2357863562 hasConcept C126322002 @default.
- W2357863562 hasConcept C141071460 @default.
- W2357863562 hasConcept C143998085 @default.
- W2357863562 hasConcept C2775930923 @default.
- W2357863562 hasConcept C2776694085 @default.
- W2357863562 hasConcept C2777292972 @default.
- W2357863562 hasConcept C2778239845 @default.
- W2357863562 hasConcept C2778822529 @default.
- W2357863562 hasConcept C2780350996 @default.
- W2357863562 hasConcept C2780835546 @default.
- W2357863562 hasConcept C2780873365 @default.
- W2357863562 hasConcept C29730261 @default.
- W2357863562 hasConcept C530470458 @default.
- W2357863562 hasConcept C71924100 @default.
- W2357863562 hasConcept C90924648 @default.
- W2357863562 hasConceptScore W2357863562C121608353 @default.
- W2357863562 hasConceptScore W2357863562C126322002 @default.
- W2357863562 hasConceptScore W2357863562C141071460 @default.
- W2357863562 hasConceptScore W2357863562C143998085 @default.
- W2357863562 hasConceptScore W2357863562C2775930923 @default.
- W2357863562 hasConceptScore W2357863562C2776694085 @default.
- W2357863562 hasConceptScore W2357863562C2777292972 @default.
- W2357863562 hasConceptScore W2357863562C2778239845 @default.
- W2357863562 hasConceptScore W2357863562C2778822529 @default.
- W2357863562 hasConceptScore W2357863562C2780350996 @default.
- W2357863562 hasConceptScore W2357863562C2780835546 @default.
- W2357863562 hasConceptScore W2357863562C2780873365 @default.
- W2357863562 hasConceptScore W2357863562C29730261 @default.
- W2357863562 hasConceptScore W2357863562C530470458 @default.
- W2357863562 hasConceptScore W2357863562C71924100 @default.
- W2357863562 hasConceptScore W2357863562C90924648 @default.
- W2357863562 hasLocation W23578635621 @default.
- W2357863562 hasOpenAccess W2357863562 @default.
- W2357863562 hasPrimaryLocation W23578635621 @default.
- W2357863562 hasRelatedWork W1970210435 @default.
- W2357863562 hasRelatedWork W1980544879 @default.
- W2357863562 hasRelatedWork W1999426713 @default.
- W2357863562 hasRelatedWork W2035374326 @default.
- W2357863562 hasRelatedWork W2038118950 @default.
- W2357863562 hasRelatedWork W2044573647 @default.
- W2357863562 hasRelatedWork W2078050738 @default.
- W2357863562 hasRelatedWork W2103629019 @default.
- W2357863562 hasRelatedWork W2111487955 @default.
- W2357863562 hasRelatedWork W2113016864 @default.
- W2357863562 hasRelatedWork W2124936866 @default.
- W2357863562 hasRelatedWork W2232045805 @default.
- W2357863562 hasRelatedWork W2368308075 @default.
- W2357863562 hasRelatedWork W2372419392 @default.
- W2357863562 hasRelatedWork W2402073723 @default.
- W2357863562 hasRelatedWork W2419348082 @default.
- W2357863562 hasRelatedWork W2421027699 @default.
- W2357863562 hasRelatedWork W2442041025 @default.
- W2357863562 hasRelatedWork W3001028394 @default.
- W2357863562 hasRelatedWork W3009101260 @default.
- W2357863562 isParatext "false" @default.
- W2357863562 isRetracted "false" @default.
- W2357863562 magId "2357863562" @default.
- W2357863562 workType "article" @default.